Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

What was studied

This early study tested amivantamab for head and neck cancer that returned or spread. People had already had a checkpoint inhibitor and platinum chemotherapy. The drug was given under the skin every 3 weeks. The group had 102 people with non HPV cancer. People with earlier anti-EGFR therapy or p16-positive oropharyngeal cancer were left out. The main goal was objective response rate.

What they found

On blinded central review, the objective response rate was 42, and complete response was 15. Median response duration was not reached. Median follow up was 11.8 months. Median progression free survival was 6.8 months. Median overall survival was 12.5 months. Stops due to treatment occurred at a rate of 8.

What it means for patients

The authors say amivantamab showed greater antitumor activity than reported for paclitaxel or cetuximab. This was in people who had already had immune therapy and chemotherapy. They say side effects were consistent with earlier experience, with no new safety signals.

Why it is not certain yet

This group had no comparison arm. The comparison is with earlier reports of other drugs. Median response duration was not reached. Only people with non HPV cancer and no earlier anti-EGFR therapy were included.

Source

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.